4.2 Review

Clinical and biochemical characteristic features of metastatic cancer to the sella turcica: an analytical review

Journal

PITUITARY
Volume 17, Issue 6, Pages 575-587

Publisher

SPRINGER
DOI: 10.1007/s11102-013-0542-9

Keywords

Pituitary metastasis; Pituitary mass; Diabetes insipidus; Metastatic cancer

Ask authors/readers for more resources

Background and objectives Sellar metastasis is uncommon and poorly characterized as published data include small series of subjects. This study's goal is to identify unique features that differentiate this entity from other sellar masses such as pituitary macroadenomas. Methods Published cases of pathologically-confirmed sellar metastasis along with our experience in such patients over a 6-years period were reviewed (total = 129). As a control group, we reviewed similar data on 55 patients with pituitary macroadenomas managed over the same time-period. Presenting symptoms, pituitary dysfunction were analyzed using univariate, multivariate and receiver operating characteristic (ROC) analyses. Results Sellar metastasis has equal gender distribution with a median patient-age of 56 years. The most common primary malignancy was breast cancer (29 %) in women and lung cancer (30 %) in men. Sellar metastasis was the first manifestation of cancer in over 40 % of patients. Common presenting symptoms included headaches, visual field deficits, abnormal eye motility and diabetes insipidus. These symptoms were less frequent among patients with pituitary macroadenomas. Univariate regression analyses showed that headaches, abnormal eye motility, visual field deficits and diabetes insipidus were each predictive of metastatic disease. ROC analysis combining all 4 features revealed an AUC of 0.953 with a sensitivity of 0.818 and a specificity of 0.935. Using the multivariate regression, abnormal eye motility and/or diabetes insipidus independently predicted metastatic disease. Conclusions Sellar metastasis should be suspected in patients presenting with sellar masses, abnormal eye motility and/or diabetes insipidus even those without known malignancy since pituitary metastasis can often be the first manifestation of cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biophysics

History of drug use in allogeneic hematopoietic cell transplant recipients

Mouhamed Yazan Abou-Ismail, Gayathri Ravi, Pingfu Fu, Shufen Cao, Sowjanya Vuyyala, Paolo Caimi, Merle Kolk, Nicole Ferrari, Kirsten Boughan, Brenda Cooper, Molly Gallogly, Folashade Otegbeye, Benjamin Tomlinson, Marcos de Lima, Leland Metheny

Summary: Allogeneic hematopoietic cell transplant is an effective treatment for blood diseases, but drug use may lead to adverse outcomes. A retrospective analysis of 232 patients found that drug use was associated with increased non-relapse mortality, suggesting further research with larger cohorts is needed to validate these findings.

BONE MARROW TRANSPLANTATION (2021)

Correction Biophysics

History of drug use in allogeneic hematopoietic cell transplant recipients (Sep, 10.1038/s41409-020-01058-z, 2020)

Mouhamed Yazan Abou-Ismail, Gayathri Ravi, Pingfu Fu, Shufen Cao, Sowjanya Vuyyala, Paolo Caimi, Merle Kolk, Nicole Ferrari, Kirsten Boughan, Brenda Cooper, Molly Gallogly, Folashade Otegbeye, Benjamin Tomlinson, Marcos de Lima, Leland Metheny

Summary: An amendment to this paper has been published and is accessible via a link at the top of the paper.

BONE MARROW TRANSPLANTATION (2021)

Article Oncology

Socioeconomic Factors and Survival of Multiple Myeloma Patients

Kamal Chamoun, Amin Firoozmand, Paolo Caimi, Pingfu Fu, Shufen Cao, Folashade Otegbeye, Leland Metheny, Seema Patel, Stanton L. Gerson, Kirsten Boughan, Marcos De Lima, Ehsan Malek

Summary: Multiple Myeloma patients have seen improved outcomes with the introduction of novel medications and autologous hematopoietic cell transplantation. However, economic factors and treatment facility type play an important role in their survival.

CANCERS (2021)

Article Medicine, Research & Experimental

Computerized tumor multinucleation index (MuNI) is prognostic in p16*oropharyngeal carcinoma

Can F. Koyuncu, Cheng Lu, Kaustav Bera, Zelin Zhang, Jun Xu, Paula Toro, German Corredor, Deborah Chute, Pingfu Fu, Wade L. Thorstad, Farhoud Faraji, Justin A. Bishop, Mitra Mehrad, Patricia D. Castro, Andrew G. Sikora, Lester D. R. Thompson, R. D. Chernock, Krystle A. Lang Kuhs, Jingqin Luo, Vlad Sandulache, David J. Adelstein, Shlomo Koyfman, James S. Lewis, Anant Madabhushi

Summary: MuNI is a deep-learning-based metric for prognostication in p16* OPSCC, quantifying tumor multinucleation from digitally scanned H & E-stained slides. It independently predicts treatment failure in patients with p16* OPSCC and shows promise as a low-cost digital biomarker test for counseling, treatment, and surveillance.

JOURNAL OF CLINICAL INVESTIGATION (2021)

Article Oncology

Computer extracted gland features from H&E predicts prostate cancer recurrence comparably to a genomic companion diagnostic test: a large multi-site study

Patrick Leo, Andrew Janowczyk, Robin Elliott, Nafiseh Janaki, Kaustav Bera, Rakesh Shiradkar, Xavier Farre, Pingfu Fu, Ayah El-Fahmawi, Mohammed Shahait, Jessica Kim, David Lee, Kosj Yamoah, Timothy R. Rebbeck, Francesca Khani, Brian D. Robinson, Lauri Eklund, Ivan Jambor, Harri Merisaari, Otto Ettala, Pekka Taimen, Hannu J. Aronen, Peter J. Bostrom, Ashutosh Tewari, Cristina Magi-Galluzzi, Eric Klein, Andrei Purysko, Natalie NC Shih, Michael Feldman, Sanjay Gupta, Priti Lal, Anant Madabhushi

Summary: Histotyping is an automated BCR prognosis method that is tissue non-destructive and utilizes computational image analysis of morphologic patterns in prostate tissue. Through training and validation on a large number of patients, Histotyping demonstrates good prognostic performance in various clinically stratified subsets, independently of other clinical parameters. Its performance outperforms Decipher in predicting post-RP BCR.

NPJ PRECISION ONCOLOGY (2021)

Article Oncology

Impact of effective dose to immune cells (EDIC) on lymphocyte nadir and survival in limited-stage SCLC

Yishan Yu, Pingfu Fu, Jian-Yue Jin, Siming Gao, Weili Wang, Mitchell Machtay, Linlin Wang, Feng-Ming (Spring) Kong, Jinming Yu

Summary: This study validated the significant impact of Effective Dose to Immune Cell (EDIC) on overall survival (OS) in limited-stage small cell lung cancer (LS-SCLC) patients. Specifically, EDIC plays an important predictive role in lymphocyte nadir, progression free survival (PFS) and OS in LS-SCLC.

RADIOTHERAPY AND ONCOLOGY (2021)

Article Oncology

An Imaging Biomarker of Tumor-Infiltrating Lymphocytes to Risk-Stratify Patients With HPV-Associated Oropharyngeal Cancer

German Corredor, Paula Toro, Can Koyuncu, Cheng Lu, Christina Buzzy, Kaustav Bera, Pingfu Fu, Mitra Mehrad, Kim A. Ely, Mojgan Mokhtari, Kailin Yang, Deborah Chute, David J. Adelstein, Lester D. R. Thompson, Justin A. Bishop, Farhoud Faraji, Wade Thorstad, Patricia Castro, Vlad Sandulache, Shlomo A. Koyfman, James S. Lewis, Anant Madabhushi

Summary: This study investigates whether OP-TIL, a biomarker, can separate stage I HPV-associated OPSCC patients into low-risk and high-risk groups and aid in patient selection for de-escalation clinical trials.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2022)

Article Multidisciplinary Sciences

Spatial interplay patterns of cancer nuclei and tumor-infiltrating lymphocytes (TILs) predict clinical benefit for immune checkpoint inhibitors

Xiangxue Wang, Cristian Barrera, Kaustav Bera, Vidya Sankar Viswanathan, Sepideh Azarianpour-Esfahani, Can Koyuncu, Priya Velu, Michael D. Feldman, Michael Yang, Pingfu Fu, Kurt A. Schalper, Haider Mahdi, Cheng Lu, Vamsidhar Velcheti, Anant Madabhushi

Summary: This study utilizes image analysis to capture morphologic attributes and evaluates their association with survival in lung cancer and gynecological cancer patients treated with immune checkpoint inhibitors (ICIs).

SCIENCE ADVANCES (2022)

Article Oncology

Exploring Real World Outcomes with Nivolumab Plus Ipilimumab in Patients with Metastatic Extra-Pulmonary Neuroendocrine Carcinoma (EP-NEC)

Amr Mohamed, Namrata Vijayvergia, Matthew Kurian, Lisa Liu, Pingfu Fu, Satya Das

Summary: This study retrospectively analyzed the treatment outcomes of EP-NEC patients and found that dual ICPIs showed better progression-free survival and overall survival in patients with EP-NEC in the second-line setting, compared to single ICPIs or cytotoxic chemotherapy.

CANCERS (2022)

Article Oncology

Machine Learning to Predict Risk of Relapse Using Cytologic Image Markers in Patients With Acute Myeloid Leukemia Posthematopoietic Cell Transplantation

Sara Arabyarmohammadi, Patrick Leo, Vidya Sankar Viswanathan, Andrew Janowczyk, German Corredor, Pingfu Fu, Howard Meyerson, Leland Metheny, Anant Madabhushi

Summary: Computer-extracted morphology and texture features from chromatin patterns of myeloblasts can predict post-HCT relapse and prognosticate RFS in patients with AML/MDS.

JCO CLINICAL CANCER INFORMATICS (2022)

Article Medicine, General & Internal

Deep-learning-based hepatic fat assessment (DeHFt) on non-contrast chest CT and its association with disease severity in COVID-19 infections: A multi-site retrospective study

Gourav Modanwal, Sadeer Al-Kindi, Jonathan Walker, Rohan Dhamdhere, Lei Yuan, Mengyao Ji, Cheng Lu, Pingfu Fu, Sanjay Rajagopalan, Anant Madabhushia

Summary: This study presents a deep-learning-based hepatic fat assessment (DeHFt) pipeline for segmenting and estimating liver attenuation on CT images, and investigates the association between hepatic steatosis and the severity of COVID-19 infections. The results show that DeHFt pipeline accurately assesses hepatic steatosis and reveals its association with the severity of COVID-19 infections.

EBIOMEDICINE (2022)

Article Multidisciplinary Sciences

A tumor vasculature-based imaging biomarker for predicting response and survival in patients with lung cancer treated with checkpoint inhibitors

Mehdi Alilou, Mohammadhadi Khorrami, Prateek Prasanna, Kaustav Bera, Amit Gupta, Vidya Sankar Viswanathan, Pradnya Patil, Priya Darsini Velu, Pingfu Fu, Vamsidhar Velcheti, Anant Madabhushi

Summary: The study found that the quantitative vessel tortuosity (QVT) imaging biomarker has the potential to predict the response and survival of patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitor (ICI) therapy.

SCIENCE ADVANCES (2022)

Article Oncology

Deep computational image analysis of immune cell niches reveals treatment-specific outcome associations in lung cancer

Cristian Barrera, German Corredor, Vidya Sankar Viswanathan, Ruiwen Ding, Paula Toro, Pingfu Fu, Christina Buzzy, Cheng Lu, Priya Velu, Philipp Zens, Sabina Berezowska, Merzu Belete, David Balli, Han Chang, Vipul Baxi, Konstantinos Syrigos, David L. Rimm, Vamsidhar Velcheti, Kurt Schalper, Eduardo Romero, Anant Madabhushi

Summary: The tumor immune composition has an impact on prognosis and treatment sensitivity in lung cancer. Effective adaptive immune responses are associated with better clinical outcomes after immune checkpoint blockers, while immunotherapy resistance can occur due to T-cell exhaustion, immunosuppressive signals, and regulatory cells. This study investigates a new computational pathology approach called PhenoTIL, which uses machine learning to analyze the spatial interactions and functional features of immune cell niches associated with tumor rejection and patient outcomes in non-small cell lung cancer (NSCLC). The study demonstrates the potential of PhenoTIL as a valuable biomarker for treatment-specific outcomes in NSCLC.

NPJ PRECISION ONCOLOGY (2023)

Article Oncology

CT radiomic signature predicts survival and chemotherapy benefit in stage I and II HPV-associated oropharyngeal carcinoma

Bolin Song, Kailin Yang, Vidya Sankar Viswanathan, Xiangxue Wang, Jonathan Lee, Sarah Stock, Pingfu Fu, Cheng Lu, Shlomo Koyfman, James S. Lewis, Anant Madabhushi

Summary: This study aimed to develop and validate a prognostic and predictive radiomic image signature (pRiS) using CT scans to inform survival and chemotherapy benefit in HPV-associated OPSCC. The results showed that pRiS was able to predict patient survival and determine whether chemotherapy provided additional benefit.

NPJ PRECISION ONCOLOGY (2023)

Article Oncology

Immune Checkpoint Blockade Outcome in Small-Cell Lung Cancer and Its Relationship With Retinoblastoma Mutation Status and Function

Afshin Dowlati, Ata Abbas, Timothy Chan, Brian Henick, Xuya Wang, Parul Doshi, Pingfu Fu, Jyoti Patel, Fengshen Kuo, Han Chang, David Balli

Summary: This study found that mutations in the RB1 gene are associated with survival outcomes in small-cell lung cancer (SCLC) patients treated with immune checkpoint blockade (ICB). RB1 mutant tumors showed downregulated expression of immune-related genes and an immune exclusion phenotype. SCLC patients with wild-type RB1 status or lower RB1 gene loss-of-function signature scores have better outcomes with ICB monotherapy.

JCO PRECISION ONCOLOGY (2022)

No Data Available